Experienced in Autosomal Dominant Nocturnal Frontal Lobe Epilepsy (ADNFLE)

Akihisa Okumura

Okazaki, JP 
Experienced in Autosomal Dominant Nocturnal Frontal Lobe Epilepsy (ADNFLE)
Okazaki, JP 
OverviewLocationsClinical Research

Overview

Akihisa Okumura practices in Okazaki, Japan. Okumura is rated as an Experienced expert by MediFind in the treatment of Autosomal Dominant Nocturnal Frontal Lobe Epilepsy (ADNFLE). Their top areas of expertise are Benign Familial Neonatal Seizures, West Syndrome, Genetic Epilepsy with Febrile Seizures Plus (GEFS+), Seizures, and Colonoscopy.

Their clinical research consists of co-authoring 219 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Autosomal Dominant Nocturnal Frontal Lobe Epilepsy (ADNFLE).

Locations

Okazaki, Japan
Other Locations
Nagakute, Japan
Nagoya, Japan
Tokyo, Japan
Japan
Hongo, Japan
Tenri, Japan
Kanazawa, Japan
Suita, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 3, Prospective, Open-Label, Multisite, Extension of Phase 3 Studies To Assess the Long-Term Safety and Tolerability of Soticlestat as Adjunctive Therapy in Subjects With Dravet Syndrome or Lennox-Gastaut Syndrome (ENDYMION 2)
A Phase 3, Prospective, Open-Label, Multisite, Extension of Phase 3 Studies To Assess the Long-Term Safety and Tolerability of Soticlestat as Adjunctive Therapy in Subjects With Dravet Syndrome or Lennox-Gastaut Syndrome (ENDYMION 2)
Enrollment Status: Terminated
Publish Date: October 08, 2025
Intervention Type: Drug
Study Drug: Soticlestat
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Young Adult Subjects With Dravet Syndrome (DS)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Young Adult Subjects With Dravet Syndrome (DS)
Enrollment Status: Completed
Publish Date: January 01, 2025
Intervention Type: Drug
Study Drug: Soticlestat
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Adult Subjects With Lennox-Gastaut Syndrome (LGS)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Adult Subjects With Lennox-Gastaut Syndrome (LGS)
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Drug
Study Drug: Soticlestat
Study Phase: Phase 3
A Phase 3, Open-Label, Randomized, Multicenter, 12-month, Efficacy and Safety Study of Weekly MOD-4023 Compared to Daily Genotropin® Therapy in Japanese Pre-pubertal Children With Growth Hormone Deficiency
A Phase 3, Open-Label, Randomized, Multicenter, 12-month, Efficacy and Safety Study of Weekly MOD-4023 Compared to Daily Genotropin® Therapy in Japanese Pre-pubertal Children With Growth Hormone Deficiency
Enrollment Status: Completed
Publish Date: August 12, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 3 Less Clinical Trials

219 Total Publications

National study on pediatric acute encephalopathy in Japan (April 2020 to October 2023): Insights from the third study.
National study on pediatric acute encephalopathy in Japan (April 2020 to October 2023): Insights from the third study.
Journal: Brain & development
Published: March 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Okumura's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 17 Advanced Conditions
    View All 72 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile